| Literature DB >> 30713027 |
Joan Teyra1, Alex U Singer1, Frank W Schmitges1, Patrick Jaynes2, Sarah Kit Leng Lui2, Maria J Polyak3, Nassima Fodil3, Jonathan R Krieger4, Jiefei Tong5, Carsten Schwerdtfeger6, Bradley B Brasher6, Derek F J Ceccarelli7, Jason Moffat8, Frank Sicheri9, Michael F Moran10, Philippe Gros11, Pieter J A Eichhorn12, Martin Lenter13, Guido Boehmelt14, Sachdev S Sidhu15.
Abstract
The multi-domain deubiquitinase USP15 regulates diverse eukaryotic processes and has been implicated in numerous diseases. We developed ubiquitin variants (UbVs) that targeted either the catalytic domain or each of three adaptor domains in USP15, including the N-terminal DUSP domain. We also designed a linear dimer (diUbV), which targeted the DUSP and catalytic domains, and exhibited enhanced specificity and more potent inhibition of catalytic activity than either UbV alone. In cells, the UbVs inhibited the deubiquitination of two USP15 substrates, SMURF2 and TRIM25, and the diUbV inhibited the effects of USP15 on the transforming growth factor β pathway. Structural analyses revealed that three distinct UbVs bound to the catalytic domain and locked the active site in a closed, inactive conformation, and one UbV formed an unusual strand-swapped dimer and bound two DUSP domains simultaneously. These inhibitors will enable the study of USP15 function in oncology, neurology, immunology, and inflammation.Entities:
Keywords: DUSP; TGF-β pathway; USP15; USP4; UbV; catalytic domain; deubiquitinase; phage display; ubiquitin; ubiquitin-like
Mesh:
Substances:
Year: 2019 PMID: 30713027 DOI: 10.1016/j.str.2019.01.002
Source DB: PubMed Journal: Structure ISSN: 0969-2126 Impact factor: 5.006